Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. (DRUG) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
drug · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bright Minds Biosciences Inc. (DRUG) measures how much investors pay for each dollar of the company's trailing earnings. DRUG's current PE ratio of N/A is calculated by dividing its stock price of $65.28 by its TTM earnings per share of -$2.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bright Minds Biosciences Inc.You DRUG | $507M | N/A | — | -$2.87 |
 Altimmune, Inc. ALT | $241M | N/A | — | -$1.00 |
 Annexon, Inc. ANNX | $612M | N/A | — | -$1.33 |
 Aura Biosciences, Inc. AURA | $416M | N/A | — | -$1.76 |
 DiaMedica Therapeutics Inc. DMAC | $302M | N/A | — | -$0.70 |
 Design Therapeutics, Inc. DSGN | $653M | N/A | — | -$1.22 |
 enGene Holdings Inc. ENGN | $84M | N/A | — | -$2.29 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-1.78 | — | |
2024-09-30 FY2024 | — | $-0.65 | — | |
2023-09-30 FY2023 | — | $-1.98 | — | |
2022-09-30 FY2022 | — | $-6.06 | — | |
2021-09-30 FY2021 | — | $-4.82 | — | |
2020-09-30 FY2020 | — | $-0.38 | — | |
2019-09-30 FY2019 | — | $-0.18 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bright Minds Biosciences Inc. (DRUG) measures how much investors pay for each dollar of the company's trailing earnings. DRUG's current PE ratio of N/A is calculated by dividing its stock price of $65.28 by its TTM earnings per share of -$2.87.
Frequently asked questions
DRUG pe ratio · 6 questionsDRUG's current PE ratio is N/A as of 2026-06-09, based on a stock price of $65.28 and TTM EPS of -$2.87. Data sourced from Financial Modeling Prep via DRUG's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bright Minds Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09